Towards an Industry Advisory Group An Open Round-Table Conversation 19 May 2009 Do not copy or reproduce without express written permission of Foresight.

Slides:



Advertisements
Similar presentations
Mary Ellen Turner MD, MPH Vice-President
Advertisements

December 2005 EuP Directive : A Framework for setting eco-design requirements for energy-using products European Commission.
29e CONFÉRENCE INTERNATIONALE DES COMMISSAIRES À LA PROTECTION DES DONNÉES ET DE LA VIE PRIVÉE 29 th INTERNATIONAL DATA PROTECTION AND PRIVACY COMMISSIONERS.
From Paper to Paperless Straight-through Electronic Disclosure and Abolition of Paid Announcement Requirement (The Electronic Disclosure Project) Press.
Public Procurement in Albania in the framework of recent reforms PUBLIC PROCUREMENT AGENCY 1.
1. Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Presentation to RCC Stakeholders - Webinar Session January 14 th, 2014.
CFSAN’s Peer Review for Risk Assessments Robert L. Buchanan, Sherri Dennis, and Marianne Miliotis.
Options for Regulation and the Impact of Regulation on the Marketplace 29 November 2005 Alan Kent
Introduction to the State-Level Mitigation 20/20 TM Software for Management of State-Level Hazard Mitigation Planning and Programming A software program.
3rd session: Corporate Governance
Nutrition 564: Marketing n Objectives:  Review the history of marketing  Define terms  Describe the marketing process  Identify elements to be used.
Mercer’s Climate Change Research 2011 to 2015
 2011 Johns Hopkins Bloomberg School of Public Health Regulation of Tobacco Products Mitch Zeller, JD Pinney Associates.
TELLEFSEN AND COMPANY, L.L.C. SEC Regulation SCI and Automation Review Policy Compliance March 2013 Proprietary and Confidential.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Internal Auditing and Outsourcing
XBRL Voluntary Program on the EDGAR System April 2005 Brigitte Lippmann Attorney Division of Corporation Finance Jeffrey Naumann Enabling Technologies.
DNV GL © SAFER, SMARTER, GREENER DNV GL © Second Annual Utility of the Future Pulse Survey Key Findings 1 July 15, 2015 Presentation to C/CAG RMCP.
CSO engagement in policy process Hille Hinsberg State Chancellery Government Communication Officer
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Service Provider Examinations What You Need to Know
Copyright © 2011 Pearson Education, Inc. publishing as Prentice Hall 1.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
INTRODUCTION TO RA.
Terezia Sinkova EFSA The new EU Food Safety Agency.
Update on the Family Smoking Prevention and Tobacco Control Act Mike Freiberg & Joelle Lester National Association of Chronic Disease Directors General.
EARTO – working group on quality issues – 2 nd session Anneli Karttunen, Quality Manager VTT Technical Research Centre of Finland This presentation.
 2011 Johns Hopkins Bloomberg School of Public Health Building Blocks for Effective Tobacco Product Regulation Section B.
Module N° 8 – SSP implementation plan. SSP – A structured approach Module 2 Basic safety management concepts Module 2 Basic safety management concepts.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.
Certification and Accreditation CS Phase-1: Definition Atif Sultanuddin Raja Chawat Raja Chawat.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
PSO Education for [agency/organization]’s PSES Workgroup (Presenter) (Date) 1 **For internal use by Center for Patient Safety PSO Participants. May not.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. REGULATORY INTELLIGENCE: INDUSTRY’S BEST PRACTICE OMICS 5 th International Pharmaceutical.
Chapter 5 ©2001 South-Western College Publishing Pamela S. Lewis Stephen H. Goodman Patricia M. Fandt Slides Prepared by Bruce R. Barringer University.
IESO’s Stakeholder Planning Market Operations Standing Committee Meeting Wednesday, October 19, 2005.
Environmental Management System Definitions
CHEMSTEWARDS SOCMA COMPLIANCE MORE FOR MEMBERS - VISIT SIEF and Consortium Management Issues under REACH Dr. C. T. Helmes Senior Director.
Molecule-to-Market-Place Quality
For Official Use Only National Space-Based PNT Advisory Board Mr. Michael Shaw Director National Coordination Office 28 March 2007.
Promoting excellence in social security Building on sector wide commonalities to enhance the benefits of Information.
Proposed Preliminary Statewide Full Service Partnership Classification System BASED ON STAKEHOLDER FEEDBACK THIS REPORT IS THE MENTAL HEALTH SERVICES OVERSIGHT.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
EPA P-1 Corrective Action Streamlined Consent Orders Bob Greaves Region 3 Deb Goldblum Region 3 Tom Krueger Region 5.
Date Planning for Compliance with the Final 316(b) Phase II Regulations For APPA – March 8, 2004 David E. Bailey EPRIsolutions.
FDA Regulation: The Impact on Product Development and Reporting Monica Graves Director – Marketing Operations Oversight RAI Services Company May 18, 2009.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
PLANNING Beginning of the process of management It is an intellectual process which requires a manager to think before acting. Manager of organizations.
California Department of Public Health / 1 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH Standards and Guidelines for Healthcare Surge during Emergencies How.
Company LOGO. Company LOGO PE, PMP, PgMP, PME, MCT, PRINCE2 Practitioner.
IPCC Key challenges facing communities, and approaches to solutions that enhance resilience: through NAPs Climate and Health Summit 2014 Investing.
Planning for the Future The WHY, WHAT and HOW to updating your club constitution and developing a supporting long term plan WELCOME from… Hans van Bavel.
0 Copyright © 2008 Deloitte Development LLC. All rights reserved. Dong Hee Kim, Audit Manager IFRS Conversion For seminar.
Don’t Plan to Fail so Start Strategically Planning Justin Camputaro Director of Student Centers and Activities Virginia Tech
1 From Regulatory Intelligence to Compliance Debbie Henderson Head, Global Regulatory Policy EU Ring May 13, 2014.
PRECONFERENCE III Advanced Strategies to Achieve ROI in Implementing HIPAA Karl Ideman, CEO Pool Administrators Inc. September 14, 2003.
true potential An Introduction to the First Line Manager Programme’s CMI Qualifications.
DeMystifying Advocacy As a Grantmaking Strategy June 7, 2016 Indiana Philanthropy Alliance Laurel O’Sullivan The Advocacy Collaborative, LLC.
WP3 - Evaluation and proposal selection
Update from the Faster Payments Task Force
MGT301 Principles of Marketing
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
CDRH 2010 Strategic Priorities
HOW TO FULFILL STATUTORY REQUIREMENTS ON PRODUCT RELATED HEALTH INFORMATION Samina Qureshi, M.D. PSI INTERNATIONAL Inc.
ENT 435 Competitive Success/snaptutorial.com
ENT 435 Education for Service-- snaptutorial.com.
ENT 435 Teaching Effectively-- snaptutorial.com
Employee engagement Delivery guide
Stakeholder Engagement: Webinar Part I: The Regulatory Development Process for the Government of Canada Part II: Making Technical Regulations Under.
Open Innovation Letter
Presentation transcript:

Towards an Industry Advisory Group An Open Round-Table Conversation 19 May 2009 Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website:

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: Towards an Industry Advisory Group – An Open Round-Table Conversation Faced with the product design, manufacturing, marketing and sales restrictions and requirement as well as new reporting and documentation requirements to be mandated under a new regulatory regime, what should companies be doing now to prepare their organizations and their consumers?

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: Purpose & Objectives of Today’s Discussion Facilitate preliminary discussion of guiding principles for the tobacco industry as it enters a new era of regulation Encourage active participation and presentation of differing viewpoints Lay groundwork for future discussions and industry actions 3 Ultimately, agreement on a set of actionable guiding principles will allow the tobacco industry to better adapt and respond to the challenges of a new and ever-evolving regulatory environment.

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: Panel Members NameAffiliation Farrell Delman (moderator)Tobacco Merchants Association Terry GallagherSmoker Friendly Bill GreiweCheyenne Tobacco Bill GodshallSmokefree Pennsylvania Brian HaynesTroutman Sanders John LauterbachLauterbach & Associates John MantheiLatham Watkins David O’ReillyBAT Adrian PayneTobacco Horizons Roger PennMane France Jamie PortnoffForesight Group Jim StarkeyTobacco Merchants Association Jim SwaugerRAI Lyle SmithDLC Services Uwe TrinksForesight Group

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: What Companies Should be Doing Now Required actions can be organized in three major categories: 5 Regulatory Response Regulatory Affairs Strategy Regulatory Readiness The following slides will examine these topics in more detail

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: “Regulatory Response” FDA and other health authorities will publish proposed regulations and guidelines and solicit stakeholder feedback Stakeholders, including tobacco manufacturers, will have the opportunity to provide written responses to the health authorities Tobacco can chose to either respond using the pharma industry approach or take an alternative approach 6 Traditional Pharma approach - Each individual manufacturer develops their own interpretation/application of the proposed rules, and submits their own written response to health authorities Alternative approach – Single task force composed of representatives from all manufacturers collectively discuss proposed rules and potential implications for industry, and coordinate a single written response to health authorities

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: “Regulatory Affairs Strategy” (1) Waxman Bill includes requirement for initial and periodic registration of new and existing individual tobacco products and their ingredients, including a description of tobacco, substances, compounds, and additives, including nicotine content and smoke constituents, by brand and sub-brand Documents that relate to health, toxicological, behavioral, or physiologic effects of current or future tobacco products, their constituents (including smoke constituents), ingredients, components, and additives would also require submission to health authorities In order to bring a “modified risk product” to market, a detailed product application will need to be submitted; following approval, the applicant will need to conduct post-marketing surveillance 7 Each tobacco manufacturer will need to evaluate how proposed regulations will impact their overall product strategies in both the near- and long-term

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: “Regulatory Affairs Strategy” (2) Specific regulatory strategies will need to be developed, and these should take into account: Current regulatory landscape Anticipated future regulatory landscape Emerging public policies Available regulatory pathways for approval Achievable commercial claims/target labeling Potential regulatory and/or product risks Possibility of accelerated development or exclusivity Industry will need to anticipate how the new regulatory environment will impact timelines to: Bring a new or modified product to market Efficiently and accurately register existing products with FDA Is all required information available to fulfill this requirement? Can planned product launches continue to market on schedule? 8

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: “Regulatory Affairs Strategy” (3) Stakeholders in establishment of regulatory affairs strategy: Regulatory affairs Clinical development Pharmacovigilance/drug safety Pre-clinical Sales/Marketing Manufacturing 9

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: “Regulatory Readiness” (1) Industry needs to assess their organizational, functional and technical needs following interpretation of proposed regulations New technical solutions will be required for: Safety reporting - for adverse events reported by consumers Product complaint tracking/investigation – for product complaints reported by consumers Product registration information- to manage information communicated to health authorities Corrective action/Preventative action tracking Existing technical solutions will need to undergo a functional technical assessment 10 Traditional Pharma approach - Each individual manufacturer performs their own assessment and buys/builds their own technical solutions Alternative approach - Industry performs collective assessment and establishes “global” technical industry standards and “industry technical solutions” that do not constitute a competitive advantage

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: “Regulatory Readiness” (2) Functional areas will need to be established and/or enhanced: Manufacturing Clinical development Pharmacovigilance Regulatory Affairs Tobacco manufacturers should be prepared to comply with: Good Clinical Practices Good Manufacturing Practices Good Pharmacovigilance Practices 11

Confidential Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at Or visit our website: “Regulatory Readiness” – Pharma Experience Pharma has had mixed success with the collective approach, due to several factors: Pharma can be “slow–moving” with regard to adopting new approaches Efforts to work collaboratively were initiated after each manufacturer already began to work independently Successful efforts to date have had a tremendously positive impact on business efficiencies 12